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ABSTRACT: A series of novel compounds with two halogen substituents have been designed and synthesized to further
optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was
identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors. ADMET
assays showed that compound (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG
inhibition, along with an excellent brain penetration profile. Evaluation of (+)-22a in animal models of schizophrenia-related
behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open
field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object
recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol. These data support the
further development of (+)-22a as a drug candidate for the treatment of schizophrenia.
■ INTRODUCTION
Schizophrenia is a severe mental disease that affects 1% of
the population in the US and more than 21 million people
worldwide.1 It is a disease of complex etiology with likely more
than 100 genetic loci and unspecified nongenetic contributing
factors.2,3 At least three types of symptoms exemplify schizo-
phrenia: positive, negative, and cognitive. The available anti-
psychotic drugs are effective against positive symptoms while
having minimal effects on cognitive and negative symptoms.4,5
The 5-HT2C receptor has recently been identified as a prom-
ising drug target for the treatment of a variety of central nervous
system (CNS) disorders, including obesity, schizophrenia, and
substance abuse.6,7 Lorcaserin (1, Figure 1) and vabicaserin (2)
are two representative 5-HT2C agonists that have been developed
and studied in clinical trials for these indications. Lorcaserin is the
first-in-class 5-HT2C agonist that has won FDA approval in 2012
for the treatment of obesity, and a clinical trial to evaluate its use
in smoking cessation has also been completed, with the results
remaining to be disclosed.8 Vabicaserin was studied in clinical
trials for the treatment of acute schizophrenia, in which it
demonstrated significant therapeutic effects and achieved a
proof-of-concept, but it failed to meet the primary efficacy
objective.9,10 For many years it has been appreciated that 5-HT2C
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receptor function might be altered in schizophrenia and that the
5-HT2C antagonist activity of certain atypical antipsychotic drugs
might be associated with weight gain and adverse metabolic
consequences.11−14 Advantages of the 5-HT2C receptor as a drug
target for treating schizophrenia and related disorders include
the following: (1) activation of 5-HT2C receptors specifically
decreases mesolimbic dopamine release without affecting
nigrostriatal dopamine;15 thus, it is predicted to have antipsychotic
efficacy while causing few extrapyramidal symptoms (EPS); (2)
5-HT2C agonists are known to induce weight loss, and thus such
drugs should lack the undesired side effect of weight gain and
related metabolic disorders, which have been associated with most
current antipsychotic drugs.14,16 Additionally, activation of the
5-HT2C receptor has been demonstrated to counter cognitive
deficits induced byN-methyl-D-aspartate (NMDA) antagonism,17
as well as to overcome cognitive deficits in animals bearing the
human tryptophan hydroxylase 2 (Tph2) loss of function
mutation.18 Therefore, developing safe 5-HT2C agonists for the
treatment of schizophrenia could potentially address the cognitive
deficits associated with this disease with fewer EPS and a lower risk
of causing weight gain.
The greatest challenge for developing 5-HT2C receptor
agonists is their selectivity against the other two related receptors
of the 5-HT2 subfamily, namely 5-HT2A and 5-HT2B. Activation
of 5-HT2A receptors in the CNS has been reported to be
associated with hallucinogenic effects,19 while activation of
5-HT2B receptors in the periphery produces valvulopathy and
pulmonary hypertension as has been observed with the use of
dexfenfluramine.7,20 The FDA-approved drug lorcaserin was
reported to have 100-fold selectivity for 5-HT2C relative to the
5-HT2B subtype; however, it possesses full agonist activity at
5-HT2B with moderate potency (EC50 = 943 ± 90 nM, Emax =
100%),21 and lorcaserin was reported to cause a higher incidence
of cardiac valve disorders in clinical trials compared to the
placebo group.22 We previously reported on a series of novel
compounds that have excellent selectivity for 5-HT2C receptors
which are composed of a 2-phenylcyclopropylmethylamine
scaffold.23−26 Among the reported compounds, analogues 3−6
(Figure 1) were identified to possess moderate to excellent
pharmacological profiles, and they are now undergoing further
evaluation in preclinical models.23
Due to the relatively small structural scaffold of the 2-phenyl-
cyclopropylmethylamines and the very strict steric limitations
applying to these compounds as revealed by previous structure−
activity relationship (SAR) studies, adding a second halogen
atom to the benzene ring appeared to offer a practical approach
to further enhancing ligand potency and possibly metabolic
stability. Decoration of the aromatic ring of a drug candidate with
halogen atoms, especially fluorine and chlorine, has been used
extensively in medicinal chemistry.27 The role of halogen
substituents in enhancing ligand potency as well as in optimizing
pharmacokinetic properties is well-known. The incorporation
of multihalogen atoms is exemplified by drugs not only for
peripheral diseases such as sitagliptin (7)28 and crizotinib (8)29
but also for CNS drugs such as aripiprazole (9)30 (Figure 2).
Moreover, the role of halogen binding in protein−ligand inter-
actions has been studied recently,31 and halogen bonds have been
proposed to provide molecular interactions orthogonal to
hydrogen bonds.32 The lipophilicity of halogen atoms, which
enhances the LogP values of small molecules, might also improve
the blood−brain barrier (BBB) permeability of compounds
designed for CNS indications.
Encouraged by the promising results that had been achieved
for the monohalogenated compounds,23 and the possible bene-
ficial effect of a second halogen, we synthesized a new series of
compounds containing two halogen substituents on the benzene
ring, as depicted by the general structure 10 (Figure 2). The
synthesis and SAR results are described herein, along with the
ADMET evaluation and efficacy study of a key compound in four
different schizophrenia-related animal behavioral models.
Chemical Synthesis and Pharmacological Profiling.
The synthesis of the dihalogenated compounds was achieved
employing methods similar to those reported by us previously,
starting from the corresponding benzaldehydes. Thus, various
dihalogenated benzaldehydes 11a−g were purchased or pre-
pared according to literature methods (for details, see Supporting
Information). As shown in Scheme 1, the benzaldehydes 11a−g
were converted to the corresponding acrylamides 12a−g, with
the double bond in the E configuration, using the commercially
available Wittig reagent N-methoxy-N-methyl(triphenyl-
phosphoranylidene)acetamide. This reagent was preferred over
ethyl 2-(triphenylphosphoranylidene)acetate due to the facts
that better or complete E selectivity was observed for the newly
formed double bond and that the subsequent cyclopropanation
step proceeds more efficiently with α,β-unsaturated Weinreb
amides than with esters.33,34 The acrylamides 12a−g were then
subjected to the Corey−Chaykovsky cyclopropanation reaction
to generate the cyclopropanes 13a−g as their trans isomers,
using the sulfur ylide generated from trimethylsulfoxonium
iodide by treatment with sodium hydride. Next, sequential
reduction using DIBAL-H followed by sodium borohydride
provided alcohols 14a−g in good yields. Mitsunobu reactions of
Figure 1. Structures of lorcaserin (1), vabicaserin (2), and compounds
3−6.
Figure 2. Representative drugs having a multihalogen substitution
pattern and the general structure of new 2-phenylcyclopropylmethyl-
amines.
14a−g with phthalimide produced the phthalimides 15a−g in
excellent yields. Deprotection of these imides with hydrazine
hydrate afforded the primary amines, which were protected as
their Boc intermediates 16a−g. Demethylation of intermediates
16a−g with BBr3 in dichloromethane afforded the phenol inter-
mediates 17a−g. In our previous SAR studies,23 the analogues
containing 2-fluoroethyl and allyl ether moieties were found to
provide compounds with the best pharmacological profiles.
Thus, the phenols 17a−g were converted to the 2-fluoroethyl
ethers 18a−g using Mitsunobu conditions while alkylation of
17a−g with allyl bromide afforded allyl ethers 19a−g. The
racemic compounds 16a−g, 18a−g, and 19a−g were then re-
solved by chiral preparative-HPLC to provide both the (−)- and
(+)-enantiomers, which were then deprotected withHCl in ether
to afford both enantiomers of compounds 20a−g, 21a−g, and
22a−g as their HCl salts.
All compounds were screened in functional assays at the
5-HT2C, 5-HT2B, and 5-HT2A receptors. Data were acquired
using recombinant, stably expressed human 5-HT2 receptors in
the HEK-293 cell line, using a fluorescence imaging plate reader
(FLIPR) assay as described previously.23
As shown in Table 1, a 2-methoxy substituent provides
analogues with good potency but poor selectivity for 5-HT2C,
while the 2-fluoroethoxy and allyloxy substituents afford com-
pounds with sometimes reduced but in other cases preserved
5-HT2C potency and improved selectivity.
Compared to compounds bearing a single fluorine or chlorine
group at position 5,23 those with an additional fluorine atom at
position 4 or 6 exhibited slightly modified pharmacological
profiles. In comparison to the 5,6-difluorinated compounds,
the 4,5-difluoro substitution pattern led to better potency, as
shown by the pairs (+)-20a vs (+)-20b, (+)-21a vs (+)-21b, and
(+)-22a vs (+)-22b, wherein an approximately 3-fold difference
can be observed within each pair. Importantly, the 2-fluoroethyl
and allyl ethers provided improved subtype selectivity due to loss
of potency at 5-HT2A and 5-HT2B receptors. Thus, compounds
(+)-21a, (+)-22a, (+)-21b, and (+)-22b showed moderate to
excellent profiles as selective 5-HT2C agonists. Notably, com-
pound (+)-22a represents the best of this series, exhibiting an
EC50 value of 8.7 nM at the 5-HT2C receptors, with >200-fold
selectivity over 5-HT2B and >50-fold selectivity over 5-HT2A.
Given the fact that this compound displayed very weak activation
of both the 5-HT2B receptors (Emax = 35%) and 5-HT2A receptors
(Emax = 21%), (+)-22a is a good candidate for further studies.
Considering that the 5-monofluoro analogue of (+)-22a showed
greater 5-HT2A agonist efficacy, the superiority of compound
(+)-22a over its 5-monofluoro analogue relies on its very weak
5-HT2A activity, as the latter showed greater activation of the
same receptor (EC50 = 374 nM, Emax = 56%).
23
Similarly, the 4-fluoro-5-chloro-substituted analogues pro-
vided an advantage with respect to potency compared to the
5-chloro-6-fluoro scaffold, which is illustrated by comparisons
of (+)-20c vs (+)-20d, (+)-21c vs (+)-21d, and (+)-22c vs
(+)-22d. Compound (+)-22c displayed an EC50 of 42 nM at
5-HT2C, no activity at 5-HT2A, and good selectivity over 5-HT2B
(EC50 = 1001 nM, Emax = 34%).
Scheme 1. Synthesis of Target Compounds 20a−g, 21a−g, and 22a−ga
aReagents and conditions: (a) Ph3PCHC(O)N(OMe)Me, CH2Cl2, rt, overnight; (b) Me3S+(O)I−, NaH, DMSO, rt, overnight; (c) DIBAL-H,
THF, −78 °C, 2 h; then NaBH4, MeOH, 0 °C to rt, 0.5 h; (d) phthalimide, PPh3, DEAD, THF, rt, overnight; (e) N2H4−H2O, EtOH, reflux, 3 h;
then Boc2O, Et3N, CH2Cl2, rt, 0.5 h; (f) BBr3, CH2Cl2, − 78 °C to rt, 3 h; then Boc2O, Et3N, CH2Cl2, rt, 0.5 h; (g) 2-fluoroethanol, Ph3P, DEAD,
THF, 0 to 60 °C (microwave), 1 h; (h) allyl bromide, Cs2CO3, DMF, 80 °C (microwave), 0.5−1 h; (i) (1) chiral preparative-HPLC; (2) 2 M HCl in
Et2O, rt, 24−48 h. 11−22a: 4,5-diF; 11−22b: 5,6-diF; 11−22c: 4-F, 5-Cl; 11−22d: 5-Cl, 6-F; 11−22e: 4,5-diCl; 11−22f: 5,6-diCl; 11−22g: 5-F, 6-Cl.
The introduction of a second chlorine atom which is signi-
ficantly larger than fluorine, into the 5-monochloro compound,
led to a notable change in potency and selectivity. Compound
(−)-20e, bearing a 4,5-dichloro substitution pattern, showed
midnanomolar potency at the 5-HT2C receptor (EC50 = 14 nM)
and no activity at 5-HT2B but only moderate selectivity over
5-HT2A (EC50 = 84 nM). Compound (+)-21e, with a 2-fluoro-
ethoxy group at position 2, displayed an EC50 of 18 nM and
excellent selectivity against 5-HT2B but only moderate selectivity
against 5-HT2A.
Most of the compounds above displayed the same enan-
tiomer preference as we had described previously,23 with the
Table 1. Pharmacological Profiles of Dihalogenated Compounds at 5-HT2 Receptors
a
aData were acquired with recombinant, stably expressed human 5-HT2 receptors in the HEK-293 cell line, using a fluorescence imaging plate
reader (FLIPR) assay; pEC50 and Emax values are shown as mean ± SEM (n ≥ 2); EC50s are calculated from mean pEC50 values; “NA”, no activity
(Emax < 15%) at 10 μM.
(+)-enantiomer showing greater potency. However, the
introduction of a chlorine atom at position 6, as in the compound
20f, led to the reversal of this preference. (−)-20f showed
excellent 5-HT2C potency (EC50 = 0.95 nM), 31-fold selectivity
over 5-HT2B, and 40-fold selectivity over 5-HT2A, while its
enantiomer (+)-20f was 22-fold weaker (EC50 = 21 nM) at the
5-HT2C receptor. The introduction of a slightly larger 2-alkoxy
group led to a decrease in potency, as shown by compounds 21f
and 22f. With the combination of a 5-fluoro and 6-chloro group,
similar enantiomer preference was observed for compound
20g, with the (−)-enantiomer showing higher potency (EC50 =
3.2 nM). Although (+)-20g is 7.5-fold weaker (EC50 = 24 nM)
compared to (−)-20g, it showed better selectivity against 5-HT2B
(no activity) and 5-HT2A (EC50 = 769 nM, 32-fold). Compounds
(−)-21g and (−)-22g showed only midnanomolar potency at
5-HT2C but good selectivity against both 5-HT2A and 5-HT2B
receptors (Table 1). In earlier work, based on the support of
good internal consistency of our potency data, we tacitly assumed
that enantiomers with the same sign of optical rotation as their
parents devoid of substituents on the benzene ring had the
same absolute configuration as those parents.26 An independent
determination of the any of the new compounds’ absolute
configuration has not yet been carried out, but the observed
switch of the eutomer from the (+)- to the (−)-isomer in the two
compounds mentioned above may as well result from the sign of
optical rotation for a given absolute configuration having changed
in response to the change in the substitution pattern, as from the
eutomer possessing the opposite absolute configuration in those
cases.
The SAR results of the above dihalogenated ligands further
demonstrate the strict steric limitations that apply to these
2-phenylcyclopropylmethylamine-based 5-HT2C ligands. As an
example of these steric limitations, one can consider (−)-20f and
the effect of increasing the size of its ether group frommethoxy to
allyloxy as in compound (−)-22f. This modification leads to a
∼100-fold decrease in potency (108 nM vs 0.95 nM). Also, a
∼200-fold loss in potency was observed for the 2-fluoroethoxy-
containing compound (−)-21f (224 nM vs 0.95 nM). In fact, a
decrease of greater than 2-fold in potency was observed across
all of the dihalogen-substituted compounds when the 2-alkoxy
group was changed from methoxy to allyloxy or 2-fluoroethoxy.
However, this loss in potency was accompanied by an improve-
ment in selectivity in most cases.
(+)-22a is the best compound in this series with respect to its
5-HT2C potency and selectivity against the 5-HT2B (>200-fold)
and 5-HT2A receptors (>50-fold). It was 3-fold weaker than
lorcaserin (EC50 = 2.7 nM) at 5-HT2C receptors in our assay,
but lorcaserin showed much greater activation of both 5-HT2B
(EC50 = 328 nM, Emax = 80%) and 5-HT2A receptors (EC50 =
258 nM, Emax = 67%). The low Emax values of compound (+)-22a
at both 5-HT2B and 5-HT2A receptors make it unlikely to cause
side-effects associated with the activation of those receptors. To
determine its off-target activity, compound (+)-22awas screened
against a panel of 46 targets including serotonin receptors,
dopamine receptors, adrenergic receptors, monoamine trans-
porters, andother commonCNS targets (see Supporting Information
Table S1).35 Among these, 17 targets showed greater than 50%
binding at 10 μM; thus, Ki values were determined. As shown in
Table 2, compound (+)-22a binds to 5-HT2C receptors with a Ki
value of 29 nM, while exhibiting excellent selectivity over most
other targets. Notably, compound (+)-22a binds to 5-HT2B with
a Ki = 68 nM, which indicates that the selectivity reported above
is “functional”, namely the compound binds to this receptor but
its intrinsic activity is very low (EC50 = 1745 nM, Emax = 35%).
Interestingly, compound (+)-22a also binds to the 5-HT6
receptor with a low Ki value (111 nM). Because both 5-HT6
agonists and antagonists have been shown to represent potential
therapeutics for treating cognitive deficits such as those observed
in Alzheimer’s disease (AD),36,37 the affinity of (+)-22a for this
receptor may be a desirable feature rather than represent
an undesirable side effect. We thus selected (+)-22a for further
studies of its ADMET properties and in vivo efficacy in animal
behavioral models.
ADMET Study of Compound (+)-22a. The liver micro-
somal stability of (+)-22a using both human and mouse
microsomes was assayed, and the data are shown in Table 3.
Better stability was observed in the mouse liver microsomes in
the absence of NADPH, indicating that oxidative mechanisms
are likely involved in the metabolism of this compound. In the
presence of NADPH, only 32.4% of (+)-22a remained after 2 h.
In contrast, the compound’s stability in the presence of human
liver microsomes is much better, with 70.5% of the parent
compound remaining under the same conditions. Thus, good
metabolic stability is anticipated in humans.
A frequently confronted challenge in developing CNS-
targeted drugs is insufficient blood-brain barrier (BBB) pene-
tration. Thus, compound (+)-22a was tested in mice to verify its
CNS exposure. The compoundwas administered intraperitoneally
Table 2. Binding Affinity of Compound (+)-22a at Selected
Targetsa
target pKi Ki (nM)
5-HT1A 6.03 ± 0.14 750
5-HT2A 5.80 ± 0.16 1573
5-HT2B 7.16 ± 0.12 68
5-HT2C 7.57 ± 0.05 29
5-HT6 6.94 ± 0.08 111
5-HT7 5.99 ± 0.09 1274
SERT 5.90 ± 0.10 1259
D2 5.31 ± 0.11 4898
D3 6.71 ± 0.06 201
D4 5.77 ± 0.17 1685
α2A 6.78 ± 0.31 661
α2B 6.42 ± 0.14 1549
α2C 6.56 ± 0.19 278
β2 6.09 ± 0.04 807
H2 5.47 ± 0.22 3388
M5 5.55 ± 0.07 2840
σ2 5.68 ± 0.25 2113
aBinding profiles were tested by the National Institute of Mental
Health’s Psychoactive Drug Screening Program (NIMH PDSP). Each
value of pKi is shown as mean ± SEM (n = 2−5); Ki presents the value
calculated from mean pKi.
Table 3. Liver Microsomal Stability of Compound (+)-22aa
remaining percentage (%)
HLM MLM
assay format 0 min 30 min 120 min 0 min 30 min 120 min
+ NADPH 100.0 91.9 70.5 100.0 68.1 32.4
− NADPH 100.0 94.7 81.9 100.0 97.8 79.6
aConcentration of liver microsomes was 0.5 mg/mL and (+)-22a was
tested at a concentration of 2 μM; HLM = human liver microsomes;
MLM = mouse liver microsomes.
(ip) to CD1 mice at a dose of 10 mg/kg, and both brain and
plasma concentrations were assayed at the 0.5 and 2 h time-points
(Table 4). Excellent brain penetration was observed for
compound (+)-22a, with brain/plasma concentration ratios of
29.9 and 45.0 at 0.5 and 2.0 h, respectively. The high brain
penetrance of this compound should thus maximize its exposure
in the CNS, allowing for robust activation of central 5-HT2C
receptors, while at the same time minimizing possible side effects
due to compound interactions with peripheral systems.
The inhibition of the cytochrome P450 enzymes by (+)-22a
was tested at five different isoforms, and the data are shown in
Table 5. Although a high inhibition of CYP 1A2 (86%) was
observed with (+)-22a when it was tested at a concentration of
10 μM, low inhibition was observed for the other, more abundant
isoforms, especially CYP 3A4 (3.4% inhibition at 10 μM).
Furthermore, inhibition of the human Ether-a-̀go-go related gene
(hERG) channel was also tested, and (+)-22a displayed a dose-
dependent inhibition of hERG, with an IC50 value of 9.1 μM.
This was not unexpected, as the structure of (+)-22a falls into the
common templates which are known to cause hERG inhibi-
tion.38 However, the high brain/plasma concentration ratios
found for this compound should minimize the possible cardiac
toxicity associated with hERG inhibition.
Efficacy Study of Compound (+)-22a in Animal Models
of Schizophrenia-Like Behaviors. To explore the possible
use of (+)-22a in the treatment of schizophrenia, this compound
was tested in four different animal behavioral paradigms. The
open field test was used to evaluate the ability of the compound
to decrease hyperlocomotion using d-amphetamine (AMPH) as
the stimulant, whereas the AMPH-disrupted prepulse inhibition
(PPI) test was used to analyze possible compound effects on
abnormalities in sensorimotor gating.39,40 The well-known novel
object recognition memory (NORM) test using transgenic
N-methyl-D-aspartate (NMDA) receptor NR1-knockdown
(KD) mice was conducted to assess the ability of the compound
to improve cognition.41 Lastly, the ability of (+)-22a to induce
catalepsy was evaluated and compared to haloperidol. These data
are detailed below.
Open Field Activity. The baseline activity of the mice
was assessed for 15 min before the administration of AMPH
(3 mg/kg, ip). During this period, only those mice from the
30 mg/kg (+)-22a + AMPH group showed a small, albeit
significant (p < 0.040), reduction in locomotion compared to
the Veh + AMPH group; all other groups had similar levels of
baseline activities (Figure 3A,B). Administration of AMPH induced
a significant increase in locomotor activity, as shown by the
comparison of the Veh + AMPH group with the Veh + Veh group
(Figure 3A,C). Animals given (+)-22a showed a dose-dependent
suppression of AMPH-stimulated hyperlocomotion; the 2 mg/kg
dose showed no significant efficacy while 5, 10, 20, and 30 mg/kg
significantly reduced the hyperactivity compared to the Veh +
AMPH group. Notably, locomotor activities of mice treated with
20 or 30 mg/kg (+)-22a + AMPH did not significantly differ
from animals in the 20 mg/kg (+)-22a + Veh or the Veh + Veh
control groups which had similar activity levels. Thus, a dose
of 20 or 30 mg/kg of (+)-22a reduced the animals’ activities to
normal levels.
Prepulse Inhibition (PPI). The Veh + AMPH group showed
a marked suppression of PPI compared to Veh + Veh controls
(p < 0.007) and a loss of prepulse dependency at the 8 and 12 dB
prepulse intensities (Figure 4A). The suppression was reversed
by both 0.5 (p < 0.01) and 1 mg/kg (p < 0.05) doses of (+)-22a,
and the PPI was restored in both groups. Mice treated with the
1 mg/kg dose + AMPH showed full prepulse dependency of the
PPI response, with the percentages of the PPI at 4, 8, and 12 dB
being significantly distinguished from each other (p < 0.010).
Although 2 mg/kg (+)-22a increased AMPH-disrupted PPI, this
effect was not significantly different from the Veh + AMPH
group. Mice in the 4 mg/kg (+)-22a + Veh group exhibited PPI
levels which were indistinguishable from the Veh + Veh group.
However, the 4 mg/kg dose failed to increase AMPH-disrupted
PPI.
The startle or “pulse-only” responses to the 120 dB acoustic
stimulus (Figure 4B) were similar among the Veh + Veh, 4 mg/
kg (+)-22a + Veh, Veh + AMPH, and 4mg/kg (+)-22a + AMPH
groups. In contrast, the 0.5, 1, and 2 mg/kg doses of this
compound decreased startle activities, with the 0.5 mg/kg dose
significantly reducing this response relative to the Veh + Veh,
4 mg/kg (+)-22a + Veh, Veh + AMPH, and 4 mg/kg (+)-22a +
AMPH groups (ps < 0.035). Null activities were not distin-
guished across treatment conditions, with activities averaging
10.60 ± 0.53 AU across all animals, which accounted for less
than 4% of the average pulse-only response. Together, these data
demonstrate that (+)-22a can normalize AMPH-disrupted
PPI and restore the prepulse dependency of the response, with
1 mg/kg showing the best efficacy.
Novel Object Recognition Memory (NORM). This task in
rodents is considered similar to testing declarative memory in
humans, and individuals with schizophrenia are deficient on
declarative memory tasks.42,43 We used the transgenic NR1-KD
mice since these mice represent a hypoglutamatergic model of
schizophrenia and are deficient on the NORM test.41,40
As expected, vehicle-treated wild-type (WT) mice displayed a
preference for the novel object at testing, whereas the NR1-KD
animals showed no preference for either object (p < 0.001;
Figure 5A). Administration of 1 mg/kg (+)-22a attenuated
NORM in WT animals (p < 0.010). By comparison, the 0.5 and
1 mg/kg doses increased novel object preference in NR1-KD
mice, and 1 mg/kg (+)-22a significantly enhanced this preference
relative to the vehicle-treated NR1-KD animals (p < 0.002) to a
level that was indistinguishable from the WT vehicle control.












ip 10 mg/kg 0.5 1 10120 321 31.5 29.9
2 8480 300 28.3
2.0 1 3948 96.4 41.0 45.0
2 2228 45.4 49.1
aDensity of brain tissue is calculated as 1.0 g/mL.
Table 5. Cytochrome P450 Inhibition by Compound
(+)-22aa
CYP isoform (substrate) inhibition (%) ± SEM
1A2 (phenacetin) 86.0 ± 0.25
2C9 (tolbutamide) 29.2 ± 2.2
2C19 (mephenytoin) 32.0 ± 5.3
2D6 (dextromethorphan) 43.5 ± 3.0
3A4 (midazolam) 3.4 ± 1.6
aCompound (+)-20a was tested at 10 μM (n = 2); concentration of
human liver microsomes was 0.2 mg/mL; concentrations of
phenacetin, tolbutamide, mephenytoin, dextromethorphan, and
midazolam were 40, 200, 50, 10, and 5 μM, respectively.
Hence, the 1 mg/kg dose decreased NORM in WT mice, but
augmented it in the hypoglutamatergic NR1-KD animals.
To determine whether the differences in responses between
the genotypes or among the doses of (+)-22a could be attributed
to neophobia, total object exploration times were examined both
at training and at testing for long-term memory (LTM). The
vehicle-treated NR1-KDmice were observed to spendmore time
exploring objects than WT controls at both training (p < 0.006;
Figure 5B) and testing (p < 0.032; Figure 5C). By contrast,
following administration of 0.5 or 1 mg/kg (+)-22a, object
exploration was similar between genotypes during training and
testing. Hence, the rescue of NORM in NR1-KDmice cannot be
attributed to neophobia in these mutants.
Catalepsy. We next determined whether compound (+)-22a
had any cataleptic activity as compared with the vehicle and
haloperidol responses. Catalepsy at baseline prior to injection
(time 0) was similar for all groups with time in catalepsy ≤1 s
(data not shown). One hour after injection, catalepsy was very
low in all groups given 0.01 to 30 mg/kg (+)-22a and this result
was not significantly different from that of the vehicle control
(Figure 6). In contrast, catalepsy was observed to increase in a
dose-dependent fashion with haloperidol, such that responses at
the 1 and 10 mg/kg doses were significantly higher than those
for all groups given (+)-22a as well as that for the vehicle control
(ps < 0.001). These findings demonstrate that the cataleptic
potential of (+)-22a is extremely low.
■ CONCLUSION
A new series of cyclopropylmethylamine-based 5-HT2C ligands
bearing two halogen substituents on the phenyl ring have been
designed and synthesized to further optimize this class of mole-
cules. Compound (+)-22a was identified as a potent 5-HT2C
receptor agonist (EC50 = 8.7 nM, Emax = 97%), with good
selectivity against the 5-HT2B (EC50 = 1745 nM, Emax = 35%) and
5-HT2A receptors (EC50 = 491 nM, Emax = 21%). Improved selec-
tivity over the 5-HT2A receptor has been achieved in comparison
to the analogue containing a single fluorine substituent, which
showed moderate potency at the 5-HT2A receptor as well as
higher efficacy (EC50 = 374 nM, Emax = 56%).
23 In ADMET tests,
compound (+)-22a displayed good stability in the liver micro-
Figure 3. Effects of compound (+)-22a on d-amphetamine (AMPH)-stimulated hyperlocomotion in the open field. (A) Locomotor activity in the open
field in 5 min blocks reflecting baseline responses (0−15 min) and AMPH-stimulated activity with its reduction by (+)-22a (15−120 min).
(B) Cumulative baseline locomotor activities (0−15 min). (C) Cumulative AMPH-stimulated activities and reductions in activity with (+)-22a
(15−90 min). N = 7−10 mice/treatment; *, p < 0.05, compared to the Veh + Veh group; #, p < 0.05, compared to the Veh + AMPH group.
some assays and low inhibition of the most abundant CYP
isoforms. It inhibits the hERG channel with moderate potency
(IC50 = 9.1 μM). However, a brain penetration study in mice
indicated high brain concentration/plasma concentration ratios
at 0.5 h (29.9) and 2.0 h (45.0), respectively.
Compound (+)-22a showed efficacy in schizophrenia-related
behavioral models. In the hyperdopaminergic model, it sup-
pressed AMPH-induced hyperlocomotion in the open field in a
dose-dependent manner, and it normalized the AMPH-disrupted
PPI. Furthermore, it rescued NORM in the NR1-KD mice in
the hypoglutamatergic model. Catalepsy was very low with
compound (+)-22a, as it showed effects similar to that of the
vehicle control and was significantly lower than that for
haloperidol. Although species differences at the 5-HT2A receptor
have been reported to influence the in vivo translation of 5-HT2C
selective agonists,44 ultimately we are interested in the human
species 5-HT2 receptor selectivity. Considering that 5-HT2A
agonists disrupt rather than normalize PPI and that 5-HT2A
antagonists rather than agonists suppress AMPH-induced
hyperlocomotion,45,46 our results with compound (+)-22a likely
Figure 5. Compound (+)-22a rescues novel object recognition memory in NR1-KD mice. Mice were given vehicle (Veh) or 0.5 or 1 mg/kg (+)-22a
30 min before training or at testing for long-termmemory (LTM). (A) At testing for LTM, Veh-treated wild-type (WT) controls displayed a preference
for the novel object, whereas NR1-KD mice showed no preference for either object. In contrast, 1 mg/kg (+)-22a rescued this deficit in the mutants
while producing some deficiency in the WT animals. (B, C) As a control, the duration of object exploration was examined during (B) training and
(C) LTM testing. At training and at testing, Veh-treated NR1-KDmice spent more time exploring the objects thanWTmice, while (+)-22a reduced this
exploration time to levels that were not significantly different from the WT controls. N = 9−10 mice/genotype/treatment; *, p < 0.05, (+)-22a
compared to the Veh within genotype; x, p < 0.05, NR1-KD compared to the WT vehicle.
Figure 4.Compound (+)-22a restores d-amphetamine (AMPH)-disrupted PPI in C57BL/6J mice. (A)Mice treated with vehicle−vehicle (Veh + Veh)
showed prepulse dependency in PPI. Four mg/kg (+)-22a alone did not affect PPI relative to the Veh + Veh controls. Mice administered Veh + AMPH
had a marked reduction in PPI. Treatment with 0.5, 1, or 2 mg/kg (+)-22a restored overall AMPH-disrupted PPI to the levels of the Veh + Veh group,
with 1 mg/kg fully rescuing the prepulse dependency of the response. Mice given the 4 mg/kg dose + AMPH showed a reduction in PPI similar to that
found in Veh + AMPH animals.N = 8−11 mice/treatment; *, p < 0.05, compared to the Veh + Veh control; #, p < 0.05, compared to the Veh + AMPH
group; ‡,p < 0.05, within treatment for 8 or 12 dB compared to the 4 dB response; §, p < 0.05, within treatment for 12 dB compared to the 8 dB response.
(B) Pulse-only responses during PPI testing were not affected by treatment in the (+)-22a + Veh or the Veh + AMPH groups, but when (+)-22a was
given before AMPH, the startle-only response was attenuated in the 0.5 and 2 mg/kg (+)-22a groups.N = 8−11 mice/treatment; *, p < 0.05, compared
to the Veh + Veh control; #, p < 0.05, compared to the Veh + AMPH group; + , p < 0.05 compared to 4 mg/kg (+)-22a + Veh treatment; †, p < 0.05,
compared to the 4 mg/kg (+)-22a + AMPH treatment.
do not reflect 5-HT2A activation resulting from species
differences in rodent models of schizophrenia. Taken together,
these data support the further development of compound
(+)-22a as a potential drug candidate for the treatment of
schizophrenia. This agent may cause fewer side effects while
improving cognition and avoiding weight gain in schizophrenia
patients based upon its 5-HT2C-directed mechanism of action.
■ EXPERIMENTAL SECTION
General. All chemicals and solvents were purchased from Sigma-
Aldrich or Fisher Scientific and were used as obtained without further
purification. Microwave reactions were run in a Biotage Initiator
microwave reactor. Synthetic intermediates were purified by Combi-
Flash flash chromatography on 230−400 mesh silica gel. 1H and 13C
NMR spectra were recorded on Bruker DPX-400 or AVANCE-400
spectrometers, at 400 and 100 MHz, respectively. NMR chemical shifts
were reported in δ (ppm) using residual solvent peaks as standard
(CDCl3 7.26 (H), 77.23 (C); CD3OD 3.31 (H), 49.15 (C); DMSO-d6
2.50 (H), 39.52 (C)). Mass spectra were measured using ESI with an
LCMS-IT-TOF (Shimadzu). Purity of all final compounds (greater than
95%) was determined by analytical HPLC (ACE 3AQ C18 column
(150 × 4.6 mm, particle size 3 μM); 0.05% TFA in H2O/0.05% TFA
in MeOH gradient eluting system; flow rate = 1.0 mL/min). Optical
rotation values were recorded on a Rudolph Research Autopol IV
automatic polarimeter.
Compounds 16a−g, 18a−g, and 19a−g were prepared according to
the methods depicted in Scheme 1. The synthetic procedures and
characterization data of all intermediates can be found in the Supporting
Information.
General Methods. (1) Chiral HPLC separation of racemic 16a−g,
18a−g, and 19a−g. Analytical conditions: RegisCell chiral column
(25 cm × 4.6 mm, 10 μm particle size), 1.5−15% EtOH in n-hexane as
the mobile phase; preparative conditions: RegisPack chiral column
(25 cm × 21.1 mm, 10 μm particle size), 3.0−7.5% EtOH in n-hexane as
the eluting system (isocratic eluent, stacked injections, flow rate =
18 mL/min, λ = 254 and 280 nm). Optical purities of both enantiomers
were determined with analytical HPLC after the separation, and a
second separation was performed when necessary to guarantee an
enantiomeric excess of >90%. (2) Both enantiomers of compounds
16a−g, 19a−g, and 21a−g were dissolved in 2 M HCl in diethyl ether
and stirred at room temperature for 24−48 h. The white solids formed
were collected by filtration, washed with diethyl ether, and dried under
vacuum to give compounds (−)-20a−g, (+)-20a−g, (−)-21a−g,
(+)-21a−g, (−)-22a−g, and (+)-22a−g as HCl salts.
(−)-[2-(4,5-Difluoro-2-methoxyphenyl)cyclopropyl]methanamine
Hydrochloride ((−)-20a). White solid. HPLC: 99.8%; 1H NMR
(CD3OD) δ 6.94−6.88 (m, 2H), 3.87 (s, 3H), 3.08 (dd, J = 13.2,
7.2 Hz, 1H), 2.93 (dd, J = 13.2, 8.0 Hz, 1H), 2.09−2.03 (m, 1H), 1.27−
1.23 (m, 1H), 1.13−1.08 (m, 1H), 1.04−1.00 (m, 1H); 13C NMR
(CD3OD) δ 156.2 (d, JCF = 7.4 Hz), 150.2 (dd, JCF = 242.7, 13.5 Hz),
145.5 (dd, JCF = 236.5, 12.6 Hz), 127.1, 116.4 (d, JCF = 19.2 Hz), 101.6
(d, JCF = 21.4 Hz), 56.9, 45.1, 19.5, 17.8, 13.1; HRMS calcd for
C11H14F2NO




Hydrochloride ((+)-20a). White solid. HPLC: 99.8%; 1H NMR
(CD3OD) δ 6.94−6.88 (m, 2H), 3.87 (s, 3H), 3.08 (dd, J = 13.2,
7.2 Hz, 1H), 2.93 (dd, J = 13.2, 8.0 Hz, 1H), 2.08−2.03 (m, 1H), 1.26−
1.22 (m, 1H), 1.14−1.08 (m, 1H), 1.04−0.98 (m, 1H); HRMS calcd for
C11H14F2NO




Hydrochloride ((−)-20b). White solid. HPLC: 99.6%; 1H NMR
(CD3OD) δ 7.08 (q, J = 9.6 Hz, 1H), 6.74−6.71 (m, 1H), 3.86 (s,
3H), 3.13 (dd, J = 13.2, 6.8 Hz, 1H), 2.92 (dd, J = 13.2, 8.4 Hz, 1H),
1.85−1.79 (m, 1H), 1.54−1.47 (m, 1H), 1.27−1.21 (m, 1H), 1.11−1.05
(m, 1H); 13CNMR (CD3OD) δ 156.7 (dd, JCF = 5.8, 2.0 Hz), 151.3 (dd,
JCF = 243.3, 13.8 Hz), 146.7 (dd, JCF = 237.2, 13.9 Hz), 119.3 (d, JCF =
11.4 Hz), 115.6 (d, JCF = 18.3 Hz), 106.8 (dd, JCF = 6.4, 3.5 Hz), 56.8,
45.4, 18.3, 13.6, 12.9; HRMS calcd for C11H14F2NO
+ ([M + H]+):
214.1038, found: 214.1044; [α]D
20 −36.9 (c 0.7, MeOH).
(+)-[2-(2,3-Difluoro-6-methoxyphenyl)cyclopropyl]methanamine
Hydrochloride ((+)-20b). White solid. HPLC: 99.8%; 1H NMR
(CD3OD) δ 7.08 (q, J = 9.6 Hz, 1H), 6.75−6.71 (m, 1H), 3.86 (s,
3H), 3.13 (dd, J = 12.8, 6.8 Hz, 1H), 2.91 (dd, J = 12.8, 8.4 Hz, 1H),
1.85−1.79 (m, 1H), 1.51−1.46 (m, 1H), 1.27−1.22 (m, 1H), 1.10−1.05
(m, 1H); HRMS calcd for C11H14F2NO
+ ([M + H]+): 214.1038, found:
214.1041; [α]D
20 +38.0 (c 0.2, MeOH).
(−)-[2-(5-Chloro-4-fluoro-2-methoxyphenyl)cyclopropyl]-
methanamine Hydrochloride ((−)-20c). White solid. HPLC: 99.2%;
1HNMR (CD3OD) δ 7.06 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 11.2 Hz, 1H),
3.89 (s, 3H), 3.08 (dd, J = 13.2, 7.2 Hz, 1H), 2.93 (dd, J = 13.2, 8.0 Hz,
1H), 2.06−2.00 (m, 1H), 1.29−1.21 (m, 1H), 1.13−1.08 (m, 1H),
1.04−0.98 (m, 1H); 13C NMR (CD3OD) δ 159.8, 158.6 (d, JCF = 235.0
Hz), 129.2, 128.0, 112.0 (d, JCF = 17.9 Hz), 101.2 (d, JCF = 25.4 Hz),
56.8, 45.1, 19.3, 17.7, 12.9; HRMS (ESI) m/z calcd for C11H14ClFNO
+
([M + H]+): 230.0742, found: 230.0719; [α]D
20 −37.4 (c 0.5, MeOH).
(+)-[2-(5-Chloro-4-fluoro-2-methoxyphenyl)cyclopropyl]-
methanamine Hydrochloride ((+)-20c). White solid. HPLC: 99.7%;
1HNMR (CD3OD) δ 7.06 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 11.2 Hz, 1H),
3.89 (s, 3H), 3.08 (dd, J = 13.2, 7.2 Hz, 1H), 2.92 (dd, J = 13.2, 8.0 Hz,
1H), 2.06−2.00 (m, 1H), 1.28−1.21 (m, 1H), 1.14−1.08 (m, 1H),
1.04−0.98 (m, 1H); 13C NMR (CD3OD) δ 159.8, 158.6 (d, JCF = 234.8
Hz), 129.2, 128.0, 112.1 (d, JCF = 17.8 Hz), 101.2 (d, JCF = 25.7 Hz),
56.8, 45.1, 19.3, 17.7, 12.9; HRMS (ESI) m/z calcd for C11H14ClFNO
+
([M + H]+): 230.0742, found: 230.0724; [α]D
20 +35.6 (c 0.5, MeOH).
(−)-[2-(3-Chloro-2-fluoro-6-methoxyphenyl)cyclopropyl]-
methanamine Hydrochloride ((−)-20d). White solid. HPLC: 98.9%;
1H NMR (CD3OD) δ 7.28 (t, J = 8.8 Hz, 1H), 6.79 (dd, J = 9.2, 1.6 Hz,
1H), 3.87 (s, 3H), 3.11 (dd, J = 13.2, 6.8 Hz, 1H), 2.90 (dd, J = 13.2,
8.0 Hz, 1H), 1.82−1.76 (m, 1H), 1.48−1.43 (m, 1H), 1.23−1.18 (m,
1H), 1.09−1.03 (m, 1H); 13CNMR (CD3OD) δ 160.1 (d, JCF = 6.6 Hz),
158.7 (d, JCF = 243.8 Hz), 129.6, 118.9 (d, JCF = 20.1 Hz), 113.9 (d, JCF =
19.3 Hz), 108.5, 56.8, 45.4, 18.4, 13.7, 13.1; HRMS (ESI) m/z calcd for
C11H14ClFNO




methanamine Hydrochloride ((+)-20d). White solid. HPLC: 99.4%;
1H NMR (CD3OD) δ 7.29 (t, J = 8.8 Hz, 1H), 6.79 (dd, J = 8.8, 1.6 Hz,
1H), 3.88 (s, 3H), 3.11 (dd, J = 12.8, 6.4 Hz, 1H), 2.90 (dd, J = 12.8,
Figure 6. Comparison of catalepsy induced by haloperidol and (+)-22a
in C57BL/6J mice with the horizontal bar test. Separate groups of mice
were injected with vehicle (Veh), or 0.01, 0.1, 1, or 10mg/kg haloperidol
(Hal), or 0.01, 0.1, 1, 10, or 30 mg/kg compound (+)-22a and evaluated
for catalepsy 60 min later. N = 8−10 mice/treatment; *, p < 0.05,
compared to the Veh control; V, p < 0.05, compared to all other groups.
8.4 Hz, 1H), 1.82−1.77 (m, 1H), 1.48−1.44 (m, 1H), 1.24−1.18 (m,
1H), 1.09−1.04 (m, 1H); 13CNMR (CD3OD) δ 160.1 (d, JCF = 6.6 Hz),
158.7 (d, JCF = 243.8 Hz), 129.6, 118.9 (d, JCF = 20.1 Hz), 113.8 (d, JCF =
19.3 Hz), 108.4, 56.8, 45.4, 18.4, 13.7, 13.0; HRMS (ESI) m/z calcd for
C11H14ClFNO
+ ([M + H]+): 230.0742, found: 230.0744; [α]D
20 +50.0
(c 0.1, MeOH).
(− ) - [2 - (4 ,5 -D ich loro-2-methoxypheny l )cyc lopropy l ] -
methanamine Hydrochloride ((−)-20e). White solid. HPLC: 99.6%;
1H NMR (CD3OD) δ 7.11 (s, 2H), 3.88 (s, 3H), 3.08 (dd, J = 13.2,
7.2 Hz, 1H), 2.92 (dd, J = 13.2, 8.0 Hz, 1H), 2.09−2.04 (m, 1H), 1.28−
1.26 (m, 1H), 1.16−1.10 (m, 1H), 1.06−1.00 (m, 1H); 13C NMR
(CD3OD) δ 159.1, 131.6, 131.5 129.2, 124.5, 113.7, 56.8, 45.0, 19.5,
17.8, 13.2; HRMS (ESI) m/z calcd for C11H14Cl2NO
+ ([M + H]+):
246.0447, found: 246.0438; [α]D
20 −37.4 (c 0.3, MeOH).
(+ ) - [2 - (4 ,5 -D ich loro-2-methoxypheny l ) cyc lopropy l ] -
methanamine Hydrochloride ((+)-20e). White solid. HPLC: 99.7%;
1H NMR (CD3OD) δ 7.11 (s, 2H), 3.89 (s, 3H), 3.08 (dd, J = 13.2,
7.6 Hz, 1H), 2.93 (dd, J = 12.8, 8.0 Hz, 1H), 2.09−2.04 (m, 1H), 1.29−
1.26 (m, 1H), 1.15−1.10 (m, 1H), 1.06−1.02 (m, 1H); 13C NMR
(CD3OD) δ 159.1, 131.6, 131.5, 129.2, 124.5, 113.7, 56.8, 45.0, 19.5,
17.8, 13.2; HRMS (ESI) m/z calcd for C11H14Cl2NO
+ ([M + H]+):
246.0447, found: 246.0441; [α]D
20 +37.7 (c 0.4, MeOH).
(− ) - [2 - (2 ,3 -D ich loro-6-methoxypheny l )cyc lopropy l ] -
methanamine Hydrochloride ((−)-20f). White solid. HPLC: 99.9%;
1H NMR (CD3OD) δ 7.40 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H),
3.88 (s, 3H), 3.06 (d, J = 7.2 Hz, 2H), 1.78−1.73 (m, 1H), 1.44−1.40
(m, 1H), 1.21−1.15 (m, 1H), 1.11−1.06 (m, 1H); 13C NMR (CD3OD)
δ 159.9, 135.9, 130.2, 129.6, 125.7, 111.7, 56.7, 45.4, 20.1, 18.3, 15.2;
HRMS (ESI) m/z calcd for C11H14Cl2NO
+ ([M + H]+): 246.0447,
found: 246.0449; [α]D
20 −62.0 (c 0.1, MeOH).
(+ ) - [2 - (2 ,3 -D ich loro-6-methoxypheny l ) cyc lopropy l ] -
methanamine Hydrochloride ((+)-20f).White solid. HPLC: 99.8%; 1H
NMR (CD3OD) δ 7.40 (d, J = 9.2Hz, 1H), 6.96 (d, J = 9.2 Hz, 1H), 3.88
(s, 3H), 3.06 (d, J = 7.2 Hz, 2H), 1.77−1.74 (m, 1H), 1.44−1.42 (m,
1H), 1.21−1.15 (m, 1H), 1.09−1.05 (m, 1H); 13C NMR (CD3OD) δ
159.9, 135.9, 130.2, 129.6, 125.7, 111.7, 56.7, 45.4, 20.1, 18.3, 15.2;
HRMS (ESI) m/z calcd for C11H14Cl2NO
+ ([M + H]+): 246.0447,
found: 246.0448; [α]D
20 +69.0 (c 0.2, MeOH).
(−)-[2-(2-Chloro-3-fluoro-6-methoxyphenyl)cyclopropyl]-
methanamine Hydrochloride ((−)-20g). White solid. HPLC: 99.7%;
1H NMR (CD3OD) δ 7.10 (t, J = 8.8 Hz, 1H), 6.92 (dd, J = 9.2, 4.4 Hz,
1H), 3.86 (s, 3H), 3.10−3.00 (m, 2H), 1.76−1.73 (m, 1H), 1.47−1.42
(m, 1H), 1.19−1.08 (m, 2H); 13C NMR (CD3OD) δ 157.1, 154.2
(d, JCF = 237.8 Hz), 129.1, 124.6 (d, JCF = 18.2 Hz), 115.5 (d, JCF = 22.9
Hz), 111.1 (d, JCF = 8.5 Hz), 56.8, 45.4, 19.6, 17.5, 14.7; HRMS (ESI)
m/z calcd for C11H14ClFNO
+ ([M + H]+): 230.0742, found: 230.0723;
[α]D
20 −66.4 (c 0.3, MeOH).
(+)-[2-(2-Chloro-3-fluoro-6-methoxyphenyl)cyclopropyl]-
methanamine Hydrochloride ((+)-20g). White solid. HPLC: 99.6%;
1H NMR (CD3OD) δ 7.10 (t, J = 8.8 Hz, 1H), 6.92 (dd, J = 9.2, 4.4 Hz,
1H), 3.86 (s, 3H), 3.10−3.00 (m, 2H), 1.76−1.73 (m, 1H), 1.47−1.43
(m, 1H), 1.19−1.07 (m, 2H); 13CNMR (CD3OD) δ 157.1, 154.2 (d, JCF
= 237.9 Hz), 129.1, 124.6 (d, JCF = 18.1 Hz), 115.5 (d, JCF = 22.9 Hz),
111.1 (d, JCF = 8.4 Hz), 56.8, 45.4, 19.6, 17.5, 14.7; HRMS (ESI) m/z
calcd for C11H14ClFNO
+ ([M + H]+): 230.0742, found: 230.0758;
[α]D
20 +69.4 (c 0.3, MeOH).
(−)-[2-[4,5-Difluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21a). White solid. HPLC: 99.7%;
1H NMR (CD3OD) δ 6.99−6.93 (m, 2H), 4.88−4.74 (m, 2H), 4.32−
4.22 (m, 2H), 3.03−3.00 (m, 2H), 2.11−2.08 (m, 1H), 1.25−1.15
(m, 2H), 1.05−1.01 (m, 1H); 13C NMR (CD3OD) δ 155.0 (dd, JCF =
7.4, 2.0 Hz), 150.1 (dd, JCF = 243.0, 13.5 Hz), 145.8 (dd, JCF = 237.3,
12.6 Hz), 127.6, 116.6 (d, JCF = 19.5 Hz), 102.9 (d, JCF = 21.4 Hz), 83.4
(d, JCF = 166.9 Hz), 69.9 (d, JCF = 18.8 Hz), 44.9, 19.7, 17.8, 12.8; HRMS
calcd for C12H15F3NO
+ ([M +H]+): 246.1100, found: 246.1106; [α]D
20
−1.5 (c 0.4, MeOH).
(+)-[2-[4,5-Difluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-21a). White solid. HPLC: 99.5%;
1H NMR (CD3OD) δ 6.99−6.93 (m, 2H), 4.88−4.74 (m, 2H), 4.32−
4.22 (m, 2H), 3.03−3.00 (m, 2H), 2.11−2.07 (m, 1H), 1.24−1.15
(m, 2H), 1.05−1.00 (m, 1H); HRMS calcd for C12H15F3NO+
([M + H]+): 246.1100, found: 246.1086; [α]D
20 +1.4 (c 0.1, MeOH).
(−)-[2-[2,3-Difluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21b). White solid. HPLC: 99.6%;
1H NMR (CD3OD) δ 7.09 (q, J = 9.6 Hz, 1H), 6.77−6.73 (m, 1H),
4.88−4.86 (m, 1H), 4.77−4.74 (m, 1H), 4.31−4.20 (m, 2H), 3.10 (dd,
J = 13.2, 7.6 Hz, 1H), 2.99 (dd, J = 13.2, 7.6 Hz, 1H), 1.89−1.84 (m,
1H), 1.56−1.53 (m, 1H), 1.35−1.31 (m, 1H), 1.12−1.07 (m, 1H); 13C
NMR (CD3OD) δ 155.6 (dd, JCF = 5.6, 2.1 Hz), 151.4 (dd, JCF = 243.7,
13.9 Hz), 147.0 (dd, JCF = 238.0, 13.8 Hz), 119.9 (d, JCF = 11.5 Hz),
115.6 (d, JCF = 18.3 Hz), 108.2 (dd, JCF = 3.6 Hz), 83.4 (d, JCF = 167.1
Hz), 69.7 (d, JCF = 18.9 Hz), 45.2, 18.4, 13.8, 12.9; HRMS calcd for
C12H15F3NO




methanamine Hydrochloride ((+)-21b). White solid. HPLC: 99.3%;
1H NMR (CD3OD) δ 7.09 (q, J = 9.6 Hz, 1H), 6.77−6.73 (m, 1H),
4.88−4.85 (m, 1H), 4.76−4.74 (m, 1H), 4.31−4.20 (m, 2H), 3.09 (dd,
J = 13.2, 7.6 Hz, 1H), 2.99 (dd, J = 12.8, 7.6 Hz, 1H), 1.89−1.84 (m,
1H), 1.56−1.53 (m, 1H), 1.35−1.31 (m, 1H), 1.12−1.07 (m, 1H);
HRMS calcd for C12H15F3NO
+ ([M + H]+): 246.1100, found:
246.1088; [α]D
20 +30.2 (c 0.2, MeOH).
(−)-[2-[5-Chloro-4-fluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21c). White solid. HPLC: 99.2%;
1HNMR (CD3OD) δ 7.10 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 11.2 Hz, 1H),
4.86−4.76 (m, 2H), 4.35−4.24 (m, 2H), 3.05−2.97 (m, 2H), 2.10−2.04
(m, 1H), 1.26−1.15 (m, 2H), 1.05−1.00 (m, 1H); 13C NMR (CD3OD)
δ 158.6, 158.5 (d, JCF = 244.2 Hz), 129.5, 128.3, 112.7 (d, JCF = 17.8 Hz),
102.3 (d, JCF = 25.4 Hz), 83.3 (d, JCF = 167.0 Hz), 69.7 (d, JCF =
18.8 Hz), 45.0, 19.5, 17.8, 12.6; HRMS calcd for C12H15ClF2NO
+
([M + H]+): 262.0805, found: 262.0782; [α]D
20 −26.4 (c 0.5, MeOH).
(+)-[2-[5-Chloro-4-fluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-21c). White solid. HPLC: 99.3%;
1HNMR (CD3OD) δ 7.10 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 10.8 Hz, 1H),
4.86−4.75 (m, 2H), 4.34−4.24 (m, 2H), 3.04−2.98 (m, 2H), 2.09−2.04
(m, 1H), 1.25−1.15 (m, 2H), 1.05−1.00 (m, 1H); 13C NMR (CD3OD)
δ 158.6, 158.5 (d, JCF = 243.9 Hz), 129.5, 128.3, 112.7 (d, JCF = 17.5 Hz),
102.3 (d, JCF = 25.5 Hz), 83.3 (d, JCF = 167.1 Hz), 69.7 (d, JCF =
19.0 Hz), 45.0, 19.5, 17.8, 12.6; HRMS calcd for C12H15ClF2NO
+ ([M +
H]+): 262.0805, found: 262.0788; [α]D
20 +28.4 (c 0.5, MeOH).
(−)-[2-[3-Chloro-2-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21d). White solid. HPLC: 98.8%;
1H NMR (CD3OD) δ 7.29 (t, J = 8.8 Hz, 1H), 6.81 (d, J = 9.2 Hz, 1H),
4.88−4.83 (m, 1H), 4.77−4.75 (m, 1H), 4.35−4.21 (m, 2H), 3.09 (dd,
J = 13.2, 7.2 Hz, 1H), 2.98 (dd, J = 13.2, 7.6 Hz, 1H), 1.88−1.83 (m,
1H), 1.55−1.51 (m, 1H), 1.32−1.28 (m, 1H), 1.12−1.06 (m, 1H); 13C
NMR (CD3OD) δ 159.0 (d, JCF = 6.4 Hz), 158.7 (d, JCF = 244.0 Hz),
129.5, 119.4 (d, JCF = 14.7 Hz), 114.4 (d, JCF = 19.2 Hz), 109.5, 83.3 (d,
JCF = 167.4 Hz), 69.6 (d, JCF = 19.0 Hz), 45.3, 18.5, 13.9, 13.1; HRMS
calcd for C12H15ClF2NO
+ ([M + H]+): 262.0805, found: 262.0791;
[α]D
20 −53.0 (c 0.3, MeOH).
(+)-[2-[3-Chloro-2-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-21d). White solid. HPLC: 99.3%;
1H NMR (CD3OD) δ 7.29 (t, J = 8.8 Hz, 1H), 6.81 (dd, J = 8.8, 1.4 Hz,
1H), 4.88−4.83 (m, 1H), 4.77−4.74 (m, 1H), 4.33−4.23 (m, 2H), 3.10
(dd, J = 12.8, 7.2 Hz, 1H), 2.98 (dd, J = 13.2, 7.6 Hz, 1H), 1.88−1.83 (m,
1H), 1.55−1.51 (m, 1H), 1.32−1.28 (m, 1H), 1.12−1.06 (m, 1H); 13C
NMR (CD3OD) δ 159.0 (d, JCF = 6.5 Hz), 158.7 (d, JCF = 244.4 Hz),
129.5, 119.4 (d, JCF = 14.7 Hz), 114.4 (d, JCF = 19.3 Hz), 109.5, 83.3 (d,
JCF = 167.3 Hz), 69.6 (d, JCF = 19.0 Hz), 45.3, 18.5, 13.9, 13.1; HRMS
calcd for C12H15ClF2NO
+ ([M + H]+): 262.0805, found: 246.0793;
[α]D
20 +53.5 (c 0.4, MeOH).
(−)-[2-[4,5-Dichloro-2-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21e). White solid. HPLC: 99.6%;
1H NMR (CD3OD) δ 7.16 (s, 1H), 7.15 (s, 1H), 4.88−4.74 (m, 2H),
4.37−4.25 (m, 2H), 3.04−3.02 (m, 2H), 2.13−2.08 (m, 1H), 1.29−1.25
(m, 1H), 1.23−1.18 (m, 1H), 1.08−1.01 (m, 1H); HRMS calcd for
C12H15Cl2FNO




methanamine Hydrochloride ((+)-21e). White solid. HPLC: 99.4%;
1H NMR (CD3OD) δ 7.16 (s, 1H), 7.15 (s, 1H), 4.88−4.75 (m, 2H),
4.36−4.24 (m, 2H), 3.04−3.01 (m, 2H), 2.13−2.08 (m, 1H), 1.29−1.26
(m, 1H), 1.23−1.19 (m, 1H), 1.08−1.03 (m, 1H); 13C NMR (CD3OD)
δ 158.1, 131.9, 131.6, 129.5, 125.1, 114.8, 83.3 (d, JCF = 167.1 Hz), 69.7
(d, JCF = 18.9Hz), 44.9, 19.7, 17.9, 12.9;HRMS calcd for C12H15Cl2FNO
+
([M + H]+): 278.0509, found: 278.0508; [α]D
20 +30.2 (c 0.5, MeOH).
(−)-[2-[2,3-Dichloro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21f). White solid. HPLC: 99.3%;
1H NMR (DMSO-d6) δ 8.09 (br, 3H), 7.48 (d, J = 8.8 Hz, 1H), 7.03 (d,
J = 8.8 Hz, 1H), 4.90−4.73 (m, 2H), 4.32−4.22 (m, 2H), 3.26−3.22 (m,
1H), 2.64−2.59 (m, 1H), 1.78−1.73 (m, 1H), 1.45−1.41 (m, 1H),
1.18−1.12 (m, 1H), 1.04−1.00 (m, 1H); 13CNMR (DMSO-d6) δ 157.1,
133.8, 128.8, 128.6, 123.5, 112.4, 82.2 (d, JCF = 165.6 Hz), 68.1 (d, JCF =
18.6 Hz), 42.7, 18.7, 16.9, 14.0; HRMS calcd for C12H15Cl2FNO
+ ([M +
H]+): 278.0509, found: 278.0494; [α]D
20 −96.0 (c 0.1, MeOH).
(+)-[2-[2,3-Dichloro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-21f).White solid. HPLC: 99.0%; 1H
NMR (DMSO-d6) δ 8.11 (br, 3H), 7.47 (d, J = 8.8 Hz, 1H), 7.03 (d, J =
8.8 Hz, 1H), 4.89−4.73 (m, 2H), 4.32−4.22 (m, 2H), 3.24 (dd, J = 12.4,
5.2 Hz, 1H), 2.64−2.59 (m, 1H), 1.78−1.73 (m, 1H), 1.45−1.41 (m,
1H), 1.18−1.13 (m, 1H), 1.04−1.00 (m, 1H); 13C NMR (DMSO-d6) δ
157.0, 133.7, 128.8, 128.6, 123.5, 112.4, 82.2 (d, JCF = 165.6 Hz), 68.1 (d,
JCF = 18.6 Hz), 42.7, 18.6, 16.9, 13.9; HRMS calcd for C12H15Cl2FNO
+
([M + H]+): 278.0509, found: 278.0493; [α]D
20 +70.0 (c 0.1, MeOH).
(−)-[2-[2-Chloro-3-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-21g). White solid. HPLC: 99.1%;
1H NMR (CD3OD) δ 7.11 (t, J = 8.8 Hz, 1H), 6.94 (dd, J = 9.0, 4.2 Hz,
1H), 4.88−4.85 (m, 1H), 4.77−4.74 (m, 1H), 4.32−4.20 (m, 2H), 3.34
(dd, J = 13.2, 6.4 Hz, 1H), 2.85 (dd, J = 13.2, 8.8 Hz, 1H), 1.85−1.79 (m,
1H), 1.56−1.50 (m, 1H), 1.23−1.18 (m, 2H); 13C NMR (CD3OD) δ
156.0, 154.5 (d, JCF = 238.6 Hz), 129.7, 124.7 (d, JCF = 18.2 Hz), 115.5
(d, JCF = 22.9 Hz), 112.6 (d, JCF = 7.6 Hz), 83.4 (d, JCF = 167.3 Hz), 69.8
(d, JCF = 18.9 Hz), 45.3, 19.7, 17.7, 14.7; HRMS calcd for
C12H15ClF2NO
+ ([M + H]+): 262.0805, found: 262.0801; [α]D
20
−54.5 (c 0.2, MeOH).
(+)-[2-[2-Chloro-3-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-21g). White solid. HPLC: 99.2%;
1H NMR (CD3OD) δ 7.11 (t, J = 8.8 Hz, 1H), 6.94 (dd, J = 9.0, 4.2 Hz,
1H), 4.88−4.85 (m, 1H), 4.78−4.74 (m, 1H), 4.33−4.20 (m, 2H), 3.34
(dd, J = 13.2, 8.8 Hz, 1H), 2.85 (dd, J = 13.2, 8.8 Hz, 1H), 1.85−1.79 (m,
1H), 1.56−1.52 (m, 1H), 1.24−1.17 (m, 2H); 13C NMR (CD3OD) δ
156.0, 154.5 (d, JCF = 238.6 Hz), 129.7, 124.7 (d, JCF = 18.2 Hz), 115.5
(d, JCF = 22.8 Hz), 112.6 (d, JCF = 7.7 Hz), 83.4 (d, JCF = 167.3 Hz), 69.8
(d, JCF = 19.0 Hz), 45.3, 19.7, 17.7, 14.7; HRMS calcd for
C12H15ClF2NO
+ ([M + H]+): 262.0805, found: 262.0807; [α]D
20
+61.4 (c 0.3, MeOH).
(−)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine
Hydrochloride ((−)-22a). White solid. HPLC: 99.3%; 1H NMR
(CD3OD) δ 6.95−6.88 (m, 2H), 6.18−6.08 (m, 1H), 5.47 (dd, J =
17.2, 1.6 Hz, 1H), 5.33 (dd, J = 10.4, 1.6 Hz, 1H), 4.60 (d, J = 5.2 Hz,
2H), 3.07 (dd, J = 12.8, 7.2 Hz, 1H), 2.98 (dd, J = 13.2, 8.0 Hz, 1H),
2.17−2.09 (m, 1H), 1.33−1.29 (m, 1H), 1.13−1.02 (m, 2H); 13C NMR
(CD3OD) δ 155.0 (dd, JCF = 7.6, 2.0 Hz), 150.0 (dd, JCF = 242.8,
13.5 Hz), 145.7 (dd, JCF = 236.9, 12.7 Hz), 134.5, 127.5, 118.6, 116.2 (d,
JCF = 19.2 Hz), 103.1 (d, JCF = 21.3 Hz), 71.1, 45.1, 19.4, 18.0, 13.4;
HRMS calcd for C13H16F2NO
+ ([M + H]+): 240.1194, found:
240.1189; [α]D
20 −14.0 (c 0.4, MeOH).
(+)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine
Hydrochloride ((+)-22a). White solid. HPLC: 99.4%; 1H NMR
(CD3OD) δ 6.94−6.89 (m, 2H), 6.18−6.08 (m, 1H), 5.47 (dd, J =
17.2, 1.6 Hz, 1H), 5.33 (dd, J = 10.8, 1.6Hz, 1H), 4.60 (d, J = 5.2Hz, 2H),
3.06 (dd, J = 13.2, 7.2 Hz, 1H), 2.97 (dd, J = 13.2, 7.6 Hz, 1H), 2.17−2.08
(m, 1H), 1.33−1.28 (m, 1H), 1.13−1.02 (m, 2H); HRMS calcd for
C13H16F2NO




Hydrochloride ((−)-22b). White solid. HPLC: 97.0%; 1H NMR
(CD3OD) δ 7.06 (q, J = 9.6 Hz, 1H), 6.75−6.71 (m, 1H), 6.16−6.09
(m, 1H), 5.46 (dd, J = 17.2, 1.6 Hz, 1H), 5.32 (dd, J = 10.8, 1.6 Hz, 1H),
4.59 (d, J = 5.6 Hz, 2H), 3.08 (dd, J = 13.2, 7.6 Hz, 1H), 3.01 (dd, J =
13.2, 7.6 Hz, 1H), 1.91−1.86 (m, 1H), 1.61−1.56 (m, 1H), 1.31−1.27
(m, 1H), 1.12−1.08 (m, 1H); 13C NMR (CD3OD) δ 155.7 (d, JCF =
5.6 Hz), 151.3 (dd, JCF = 243.3, 14.0 Hz), 146.8 (dd, JCF = 237.6,
13.8 Hz), 134.6, 119.7 (d, JCF = 11.2Hz), 118.6, 115.5 (d, JCF = 18.3 Hz),
108.5, 71.1, 45.3, 18.3, 13.9, 13.0; HRMS calcd for C13H16F2NO
+ ([M +
H]+): 240.1194, found: 240.1188; [α]D
20 −46.8 (c 0.5, MeOH).
(+)-[2-[6-(Allyloxy)-2,3-difluorophenyl]cyclopropyl]methanamine
Hydrochloride ((+)-22b). White solid. HPLC: 99.7%; 1H NMR
(CD3OD) δ 7.06 (q, J = 9.6 Hz, 1H), 6.75−6.71 (m, 1H), 6.16−6.08
(m, 1H), 5.46 (dd, J = 17.2, 1.6 Hz, 1H), 5.32 (dd, J = 10.4, 1.6 Hz, 1H),
4.59 (d, J = 5.6 Hz, 2H), 3.07 (dd, J = 13.2, 7.6 Hz, 1H), 3.00 (dd, J =
13.2, 7.6 Hz, 1H), 1.91−1.85 (m, 1H), 1.60−1.56 (m, 1H), 1.31−1.26
(m, 1H), 1.11−1.06 (m, 1H); HRMS calcd for C13H16F2NO+ ([M +
H]+): 240.1194, found: 240.1191; [α]D
20 +41.6 (c 0.2, MeOH).
(−)-[2-[2-(Allyloxy)-5-chloro-4-fluorophenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-22c). White solid. HPLC: 99.8%;
1HNMR (CD3OD) δ 7.07 (d, J = 8.4 Hz, 1H), 6.90 (d, J = 11.2 Hz, 1H),
6.18−6.08 (m, 1H), 5.47 (dd, J = 13.6, 1.6 Hz, 1H), 5.34 (dd, J = 10.4,
1.6 Hz, 1H), 4.62 (d, J = 5.2 Hz, 2H), 3.06 (dd, J = 12.8, 7.2 Hz, 1H),
2.98 (dd, J = 12.8, 8.0 Hz, 1H), 2.11−2.05 (m, 1H), 1.32−1.28 (m, 1H),
1.13−1.01 (m, 2H); 13C NMR (CD3OD) δ 158.5, 158.4 (d, JCF =
243.8 Hz), 134.3, 129.2, 128.3, 118.8, 112.3 (d, JCF = 17.6 Hz), 102.4 (d,
JCF = 25.4 Hz), 70.9, 45.0, 19.2, 17.9, 13.2; HRMS (ESI) m/z calcd for
C13H16ClFNO




methanamine Hydrochloride ((+)-22c). White solid. HPLC: 99.3%;
1HNMR (CD3OD) δ 7.07 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 11.2 Hz, 1H),
6.17−6.08 (m, 1H), 5.47 (dd, J = 13.6, 1.6 Hz, 1H), 5.34 (dd, J = 11.2,
1.2 Hz, 1H), 4.62 (d, J = 5.2 Hz, 2H), 3.06 (dd, J = 11.2, 7.2 Hz, 1H),
2.99 (dd, J = 12.8, 5.6 Hz, 1H), 2.11−2.05 (m, 1H), 1.32−1.28 (m, 1H),
1.13−1.01 (m, 2H); 13C NMR (CD3OD) δ 158.5, 158.4 (d, JCF =
243.7 Hz), 134.3, 129.2, 128.3, 118.8, 112.3 (d, JCF = 17.6 Hz), 102.4 (d,
JCF = 25.4 Hz), 70.9, 45.0, 19.2, 17.9, 13.2; HRMS (ESI) m/z calcd for
C13H16ClFNO




methanamine Hydrochloride ((−)-22d). White solid. HPLC: 98.5%;
1H NMR (CD3OD) δ 7.26 (t, J = 8.4 Hz, 1H), 6.79 (d, J = 9.2 Hz, 1H),
6.17−6.07 (m, 1H), 5.46 (d, J = 17.2 Hz, 1H), 5.33 (d, J = 10.4 Hz, 1H),
4.61 (d, J = 5.2 Hz, 2H), 3.08−2.97 (m, 2H), 1.88−1.83 (m, 1H), 1.59−
1.52 (m, 1H), 1.28−1.22 (m, 1H), 1.11−1.06 (m, 1H); 13C NMR
(CD3OD) δ 159.0 (d, JCF = 6.4 Hz), 158.7 (d, JCF = 243.9 Hz), 134.4,
129.4, 119.2 (d, JCF = 14.6 Hz), 118.7, 113.9 (d, JCF = 19.3 Hz), 109.7,
70.9, 45.3, 18.4, 13.9, 13.1; HRMS (ESI) m/z calcd for C13H16ClFNO
+
([M + H]+): 256.0899, found: 256.0900; [α]D
20 −54.0 (c 0.3, MeOH).
(+)-[2-[6-(Allyloxy)-3-chloro-2-fluorophenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-22d). White solid. HPLC: 99.6%;
1H NMR (CD3OD) δ 7.26 (t, J = 8.6 Hz, 1H), 6.79 (dd, J = 9.2, 1.6 Hz,
1H), 6.17−6.07 (m, 1H), 5.46 (dd, J = 17.2, 1.4 Hz, 1H), 5.33 (dd, J =
10.4, 1.2 Hz, 1H), 4.61 (d, J = 5.6 Hz, 2H), 3.08−2.97 (m, 2H), 1.88−
1.83 (m, 1H), 1.57−1.52 (m, 1H), 1.28−1.22 (m, 1H), 1.11−1.06 (m,
1H); 13C NMR (CD3OD) δ 159.0 (d, JCF = 6.6 Hz), 158.7 (d, JCF =
243.8 Hz), 134.4, 129.4, 119.2 (d, JCF = 14.5 Hz), 118.7, 113.9 (d, JCF =
19.2 Hz), 109.7, 70.9, 45.3, 18.4, 13.9, 13.1; HRMS (ESI) m/z calcd for
C13H16ClFNO
+ ([M + H]+): 256.0899, found: 256.0901; [α]D
20 +55.0
(c 0.2, MeOH).
(− ) - [2- [2- (A l ly loxy) -4 ,5-d ich lorophenyl ]cyc lopropyl ] -
methanamine Hydrochloride ((−)-22e). White solid. HPLC: 99.1%;
1H NMR (CD3OD) δ 7.12 (s, 1H), 7.10 (s, 1H), 6.17−6.07 (m, 1H),
5.47 (dd, J = 17.6, 1.6 Hz, 1H), 5.34 (dd, J = 10.4, 1.6 Hz, 1H), 4.63
(d, J = 5.2 Hz, 2H), 3.08−2.97 (m, 2H), 2.14−2.09 (m, 1H), 1.37−1.32
(m, 1H), 1.15−1.03 (m, 2H); 13C NMR (CD3OD) δ 157.9, 134.3,
131.9, 131.4, 129.2, 124.7, 118.7, 115.0, 70.9, 44.9, 19.4, 17.9, 13.5;
HRMS (ESI) m/z calcd for C13H16Cl2NO
+ ([M + H]+): 272.0603,
found: 272.0596; [α]D
20 −35.0 (c 0.4, MeOH).
(+) - [2- [2- (A l ly loxy) -4 ,5-d ich lorophenyl ]cyc lopropy l ] -
methanamine Hydrochloride ((+)-22e). White solid. HPLC: 99.2%;
1H NMR (CD3OD) δ 7.12 (s, 1H), 7.10 (s, 1H), 6.17−6.07 (m, 1H),
5.47 (dd, J = 17.2, 1.2 Hz, 1H), 5.34 (d, J = 10.4 Hz, 1H), 4.63 (d, J =
5.2 Hz, 2H), 3.08−2.96 (m, 2H), 2.14−2.09 (m, 1H), 1.39−1.32 (m,
1H), 1.15−1.03 (m, 2H); 13C NMR (CD3OD) δ 157.9, 134.3, 131.9,
131.4, 129.2, 124.7, 118.7, 115.0, 70.9, 44.9, 19.4, 17.9, 13.5; HRMS
(ESI) m/z calcd for C13H16Cl2NO
+ ([M + H]+): 272.0603, found:
272.0597; [α]D
20 +37.6 (c 0.3, MeOH).
(− ) - [2- [6- (A l ly loxy)-2 ,3-d ich lorophenyl ]cyc lopropy l ] -
methanamine Hydrochloride ((−)-22f). White solid. HPLC: 98.3%;
1H NMR (CD3OD) δ 7.37 (d, J = 9.2 Hz, 1H), 6.94 (d, J = 9.2 Hz, 1H),
6.18−6.08 (m, 1H), 5.46 (dd, J = 17.2, 1.6 Hz, 1H), 5.34 (dd, J = 10.8,
1.2 Hz, 1H), 4.62 (d, J = 5.2 Hz, 2H), 3.30 (dd, J = 13.2, 8.8 Hz, 1H),
2.86 (dd, J = 13.2, 8.8 Hz, 1H), 1.83−1.77 (m, 1H), 1.48−1.45 (m, 1H),
1.23−1.12 (m, 2H); 13C NMR (CD3OD) δ 158.8, 135.9, 134.4, 130.0,
129.9, 125.8, 118.9, 113.3, 70.9, 45.3, 20.2, 18.5, 15.3; HRMS (ESI)m/z
calcd for C13H16Cl2NO
+ ([M + H]+): 272.0603, found: 272.0611;
[α]D
20 −68.0 (c 0.1, MeOH).
(+) - [2- [6- (A l ly loxy) -2 ,3-d ich lorophenyl ]cyc lopropy l ] -
methanamine Hydrochloride ((+)-22f).White solid. HPLC: 99.1%; 1H
NMR (CD3OD) δ 7.37 (d, J = 8.8 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H),
6.18−6.08 (m, 1H), 5.47 (dd, J = 17.2, 1.6 Hz, 1H), 5.34 (dd, J = 10.4,
1.2 Hz, 1H), 4.63 (d, J = 5.2 Hz, 2H), 3.30 (dd, J = 12.8, 8.8 Hz, 1H),
2.86 (dd, J = 12.8, 8.8 Hz, 1H), 1.83−1.79 (m, 1H), 1.48−1.46 (m, 1H),
1.23−1.15 (m, 2H); 13C NMR (CD3OD) δ 158.8, 135.9, 134.5, 130.0,
129.9, 125.8, 118.8, 113.3, 71.0, 45.4, 20.2, 18.6, 15.3; HRMS (ESI)m/z
calcd for C13H16Cl2NO
+ ([M + H]+): 272.0603, found: 272.0596;
[α]D
20 +64.0 (c 0.1, MeOH).
(−)-[2-[6-(Allyloxy)-2-chloro-3-fluorophenyl]cyclopropyl]-
methanamine Hydrochloride ((−)-22g). White solid. HPLC: 99.7%;
1H NMR (CD3OD) δ 7.09 (t, J = 8.8 Hz, 1H), 6.92 (dd, J = 9.2, 4.4 Hz,
1H), 6.16−6.07 (m, 1H), 5.46 (dd, J = 17.6, 1.6 Hz, 1H), 5.33 (dd, J =
10.6, 1.4 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H), 3.29 (dd, J = 13.2, 6.4 Hz,
1H), 2.87 (dd, J = 12.8, 8.6 Hz, 1H), 1.84−1.77 (m, 1H), 1.53−1.47 (m,
1H), 1.22−1.17 (m, 2H); 13C NMR (CD3OD) δ 156.1, 154.3 (d, JCF =
238.3 Hz), 134.7, 129.5, 124.5 (d, JCF = 18.2 Hz), 118.7, 115.4 (d, JCF =
22.7 Hz), 112.8 (d, JCF = 7.5 Hz), 71.1, 45.4, 19.7, 17.7, 14.8; HRMS
(ESI) m/z calcd for C13H16ClFNO
+ ([M + H]+): 256.0899, found:
256.0895; [α]D
20 −52.0 (c 0.2, MeOH).
(+)-[2-[6-(Allyloxy)-2-chloro-3-fluorophenyl]cyclopropyl]-
methanamine Hydrochloride ((+)-22g). White solid. HPLC: 99.7%;
1H NMR (CD3OD) δ 7.09 (t, J = 8.8 Hz, 1H), 6.92 (dd, J = 9.2, 4.4 Hz,
1H), 6.17−6.08 (m, 1H), 5.46 (dd, J = 17.6, 1.6 Hz, 1H), 5.33 (dd, J =
10.4, 1.2 Hz, 1H), 4.60 (d, J = 4.8 Hz, 2H), 3.29 (dd, J = 13.6, 6.0 Hz,
1H), 2.87 (dd, J = 12.8, 8.8 Hz, 1H), 1.84−1.78 (m, 1H), 1.53−1.47 (m,
1H), 1.21−1.17 (m, 2H); 13C NMR (CD3OD) δ 156.1, 154.3 (d, JCF =
238.0 Hz), 134.7, 129.5, 124.5 (d, JCF = 18.1 Hz), 118.7, 115.4 (d, JCF =
22.7 Hz), 112.8 (d, JCF = 6.6 Hz), 71.1, 45.3, 19.7, 17.7, 14.8; HRMS
(ESI) m/z calcd for C13H16ClFNO
+ ([M + H]+): 256.0899, found:
256.0906; [α]D
20 +61.8 (c 0.4, MeOH).
Calcium Flux Assay. Calcium flux assay was recorded on a
FLIPRTETRA fluorescence imaging plate reader (Molecular Dynamics)
on Flp-In-293 cells stably expressing the human 5-HT2A, 5-HT2B, or
5-HT2C‑INI as previously described.
23 For each experiment, 16 concen-
trations of the compound (from 3.3× 10−13 to 1× 10−5M based on a 3.3
× serial dilution) were tested to acquire a dose−response curve.
Expression levels of the receptors were determined using saturation
binding assays, 5-HT2A: 1200 fmol/mg (
3H-ketanserin, Kd = 1.6 nM),
5-HT2B: 500 fmol/mg (
3H-lysergic acid diethylamide (LSD), Kd =
2.2 nM), and 5-HT2C: 1800 fmol/mg (
3H-mesulergine, Kd = 4.5 nM).
Off-Target Screening of Compound (+)-22a by the National
Institute of Mental Health’s Psychoactive Drug Screening
Program (NIMH PDSP). Primary binding experiments were performed
at 10 μM for compound (+)-22a, and the percentage displacement of
the radioligand was measured. Targets showing >50% inhibition of
binding at 10 μM were selected for full concentration−response
competitive binding experiments, and binding constants (Ki) were
determined. For experimental details, refer to the PDSP Web site:
http://pdspdb.unc.edu/pdspWeb/.
ADMET Tests. The liver microsomal stability study, brain
penetration test, cytochrome P450 inhibition test, and hERG inhibition
study were conducted by Pharmaron, Inc. (Beijing, China).
Animal Behavioral Methods. Animals. Adult male and female
C57BL/6J (Jackson Laboratories, Bar Harbor, ME) and NR1mice were
used for behavioral testing. All mice were between 14−18 weeks of age
at the time of testing. Mice were maintained on a 14 h light/10 h dark
light-dark cycle with the onset of the dark cycle at 2000 h. Testing was
conducted during the light cycle between 1000−1600 h. All animals
were housed by genotype and sex. Forty-eight hours before testing, mice
were weighed andmoved into the appropriate test room.Mice remained
in the test room for the duration of testing and had ad libitum access to
food and water. All studies were conducted with an approved proto-
col from the Duke University Institutional Animal Care and Use
Committee.
Drugs. Haloperidol (Sigma-Aldrich, St. Louis MO) and compound
(+)-22a were dissolved in 0.5% N,N-dimethylacetamide and 10%
(2-hydroxypropyl)-β-cyclodextrin in sterile saline. d-Amphetamine
(AMPH; Tocris Bioscience, Bristol, UK) was dissolved in sterile saline.
All treatments were delivered in a 4 mL/kg volume (ip).
Open Field Activity.Activity in the open field was assessed as distance
traveled in a novel environment (20 × 20 × 20 cm) using a Versamax
Analyzer system (Omnitech Electronics, Columbus, OH). Locomotor
activity was monitored by infrared diodes interfaced to a computer
running Fusion software (Omnitech Electronics). C57BL/6J mice
(n = 7−10 mice/treatment) were injected with vehicle (Veh) or 2, 5, 10,
20, or 30mg/kg compound (+)-22a and placed into the open field. After
15 min, each animal was removed and given Veh or 3 mg/kg AMPH and
returned immediately to the open field for an additional 105 min.
Controls consisted of separate groups of mice administered Veh-Veh or
20 mg/kg compound (+)-22a + Veh. The results are depicted as total
distance traveled in 5 min intervals over testing or cumulative distance
traveled over the 15 min of baseline and 75 min following injection of
AMPH or the vehicle.
Prepulse Inhibition. Prepulse inhibition (PPI) was assessed using the
SR Startle Lab Response system for mice (San Diego Instruments, San
Diego, CA). Adult C57BL/6J males (n = 8−11 mice/treatment group)
were administered the Veh or 0.5, 1, 2, or 4 mg/kg compound (+)-22a
followed 10 min later with Veh or 3 mg/kg AMPH. Mice were placed
into a Plexiglas holder which was positioned into the test chamber that
was interfaced to a computer running SR Lab Startle Reflex software.47
After a 10 min acclimatization period, mice were exposed to 42 test trials
composed of 18 pulse-only trials, 18 prepulse−pulse trials, and 6 null
trials. A 62 dB white noise background was present during testing. Pulse-
only trials consisted of a single 40 ms 120 dB burst of white noise.
Prepulse−pulse trials consisted of a 20 ms prepulse of white noise that
was 4, 8, or 12 dB above the 62 dB background, followed 100 ms later
with the 120 dB pulse. The white noise background was the only
stimulus present during the null only trials. Testing began and ended
with a block of five pulse-only trials; the remaining pulse-only trials were
randomized with the null trials and the prepulse−pulse trials between
these two blocks of pulse-only trials. The percent PPI for each prepulse
intensity was calculated as the ratio of the average response during the
prepulse−pulse trials to the average pulse-only responses, subtracted
from 1, multiplied by 100, and expressed as a percentage. Null activity
and pulse-only responses are reported in arbitrary units (AU) as
measured by the SR Startle Lab Response system. The peak of the startle
response (AU) was measured within a 65 ms window following onset of
the pulse-only stimulus.48
Novel Object Recognition Memory. Wild type (WT) and NR1-KD
mice (n = 9−10 mice/genotype/treatment) were randomly assigned to
three treatment groups that received Veh or 0.5 or 1 mg/kg compound
(+)-22a. Testing was conducted over 3 days with a single trial (5 min)
on each day.47 Mice were acclimated to the empty test chambers (38 ×
22 × 20 cm) on day 1 and exposed to two identical objects on day 2.
Twenty-four hours later, mice were presented with one of the same
objects from day 2 which was paired with a novel object to evaluate long-
term memory (LTM). Mice were administered Veh or compound
(+)-22a 30 min prior to the trials on days 2 and 3. All trials were video-
recorded using the Noldus Media Recorder (Noldus Technologies,
Wageningen, Netherlands), and behavioral data were analyzed using
Noldus Ethovision 10. Duration of time spent investigating the objects
was scored. The results are presented as preference scores; object
preference = (time spent with novel object−time spent with familiar
object)/total time with both objects. Positive scores denote preference
for the novel object, negative scores signify preference for the familiar
object, and scores approaching zero indicate no preference for either
object.
Catalepsy. Male C57BL/6J mice (n = 8−10 mice/treatment/time-
point) were assessed for cataleptic responses. Baseline cataleptic
responses were assessed following removal from the home-cage by
placing both front paws on a 60 cm horizontal bar (2.5 mm diameter)
elevated above the bench with both rear paws in direct contact with the
bench. Immediately following the baseline assessment, each animal was
injected with vehicle, haloperidol, or compound (+)-22a and returned
to its home cage. Catalepsy was evaluated in separate groups of mice at
60 min. The time spent in catalepsy was measured as the time following
placement to removal of the front paws from the bar, with a maximum
cutoff time of 60 s.
Statistics. All data were analyzed using SPSS 22 (IBM SPSS, Chicago,
IL) and are presented as means and standard errors of the mean (SEM).
Distance traveled in the open field was assessed with RMANOVA with
time as the within subjects effect and treatment condition as the between
subjects effect. For PPI, null and startle activities were assessed using
ANOVA with treatment as the between subjects variable. Differences in
PPI were examinedwith RMANOVAwith prepulse intensity as the within
subjects variable and treatment condition as the between subjects variable.
Responses in NORMwere evaluated using ANOVA for preference scores
in the LTM test with genotype and treatment as independent variables.
Duration of contact with the objects during the training session and the
LTM test were analyzed with RMANOVA using test-session as the within
subjects variable and genotype and treatment as the between subjects
variables. For time spent in catalepsy, a one-way ANOVA was performed
examining the effects of treatment. Posthoc comparisons were performed
with Bonferroni corrected pairwise comparisons for all analyses. In all
cases, a p < 0.05 was considered significant.
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